IMU-935 is under clinical development by Immunic and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase I drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IMU-935’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

IMU-935 overview

IMU-935 (IMU-366) is under development for the treatment of psoriasis, inflammatory bowel disease, Guillain-Barre syndrome and metastatic castration-resistant prostate cancer. IMU-366 is administered orally. The drug candidate acts by targeting retinoic acid-related orphan receptor gamma t (RORgammat), IL-17 and dihydroorotate dehydrogenase (DHODH).

Immunic overview

Immunic (Immunic Therapeutics), formerly Vital Therapies, is a biopharmaceutical company that discover, develops and commercializes oral immunology therapies to treat chronic inflammatory and autoimmune diseases. The company’s pipeline products include IMU-838, a selective immune modulator for the treatment of relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD) and other chronic inflammatory and autoimmune diseases; IMU-856, an orally small molecule modulator to treat intestinal barrier function; and IMU-935, an immunology therapy targeting ROR?t and Th17. It is also evaluating therapies targeting primary sclerosing cholangitis (PSC), and guillain-barre syndrome (GBS). Immunic Therapeutics works in collaboration with pharmaceutical and biopharmaceutical companies to develop its products. Immunic Therapeutics is headquartered in New York City, New York, the US.

For a complete picture of IMU-935’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.